These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 25426282)
1. Clinical transplantation and tolerance: are we there yet? Saidi RF; Hejazii Kenari SK Int J Organ Transplant Med; 2014; 5(4):137-45. PubMed ID: 25426282 [TBL] [Abstract][Full Text] [Related]
2. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. Feng S; Ekong UD; Lobritto SJ; Demetris AJ; Roberts JP; Rosenthal P; Alonso EM; Philogene MC; Ikle D; Poole KM; Bridges ND; Turka LA; Tchao NK JAMA; 2012 Jan; 307(3):283-93. PubMed ID: 22253395 [TBL] [Abstract][Full Text] [Related]
3. Finding the right time for weaning off immunosuppression in solid organ transplant recipients. Orlando G Expert Rev Clin Immunol; 2010 Nov; 6(6):879-92. PubMed ID: 20979553 [TBL] [Abstract][Full Text] [Related]
4. Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879 [TBL] [Abstract][Full Text] [Related]
9. History of pediatric liver transplantation. Where are we coming from? Where do we stand? Otte JB Pediatr Transplant; 2002 Oct; 6(5):378-87. PubMed ID: 12390423 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppression in the pediatric transplant recipient. Blondet NM; Healey PJ; Hsu E Semin Pediatr Surg; 2017 Aug; 26(4):193-198. PubMed ID: 28964473 [TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597 [TBL] [Abstract][Full Text] [Related]
16. Tacrolimus: a further update of its use in the management of organ transplantation. Scott LJ; McKeage K; Keam SJ; Plosker GL Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696 [TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
18. Management and prevention of post-transplant malignancies in kidney transplant recipients. Stallone G; Infante B; Grandaliano G Clin Kidney J; 2015 Oct; 8(5):637-44. PubMed ID: 26413294 [TBL] [Abstract][Full Text] [Related]
19. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681 [TBL] [Abstract][Full Text] [Related]
20. Immune tolerance and immunosuppression in solid organ transplantation. Spearman CWN; Barday ZA S Afr Med J; 2014 Oct; 104(11):7307. PubMed ID: 29183441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]